The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ANGI INC | COM CL A NEW | 00183L102 | 4,308 | 1,898 | SH | SOLE | 1,898 | 0 | 0 | |||
RECURSION PHARMACEUTICALS IN | CL A | 75629V104 | 13,152,626 | 1,971,908 | SH | SOLE | 1,971,908 | 0 | 0 | |||
ROVER GROUP INC | COM CL A | 77936F103 | 52,176,626 | 11,518,019 | SH | SOLE | 11,518,019 | 0 | 0 |